drugset / Trial / NCT00003524

Antineoplaston Therapy in Treating Patients With Stomach Cancer

NCT00003524

Phase 2 Terminated 1 enrolled Burzynski Research Institute
NaSingle-groupOpen-labelTreatment

Summary

Current therapies for Stomach Cancer provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of Stomach Cancer. PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on patients with Stomach Cancer.

Timeline

Start
1996-10-04
Primary completion
1998-08-24
Completion
1998-08-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Astugenal Unknown Intravenous
Subject antineoplaston A10 Small molecule Intravenous

Indications